» مقالات انگلیسی » Probiotics and growth in preterm infants: A randomized controlled trial, {PREMAPRO} study

Probiotics and growth in preterm infants: A randomized controlled trial, {PREMAPRO} study



شناسه مقاله
10.1016/j.clnu.2015.06.006
دریافت مقاله

انگلیسی

Title: Probiotics and growth in preterm infants: A randomized controlled trial, {PREMAPRO} study

Authors: Stephane Hays and Aurélien Jacquot and Hélène Gauthier and Christian Kempf and Anne Beissel and Odile Pidoux and Estelle Jumas-Bilak and Evelyne Decullier and Emmanuelle Lachambre and Laurence Beck and Gilles Cambonie and Guy Putet and Olivier Claris and Jean-Charles Picaud

Journal: Clinical Nutrition

Year: 2016

Abstract:

SummaryBackground & aims Recent studies have suggested that the gut microflora has metabolic effects. We aimed to evaluate postnatal growth in preterm infants who received different probiotic supplements, and to assess the safety of probiotic administration. Methods This prospective, randomized, double-blind, controlled trial was performed at three tertiary care neonatal units. Preterm infants were randomly assigned to receive daily supplementation over 4–۶ weeks with placebo (group C) or probiotics (group P). Group P comprised three subgroups: {P1} received Bifidobacterium lactis, {P2} received Bifidobacterium longum, and {P3} received B. lactis and B. longum. We assessed postnatal growth during the supplementation period and up to a corrected gestational age (GA) of 41 weeks when body composition was assessed using whole-body dual-energy X-ray absorptiometry. Aerobic and anaerobic blood cultures were performed on suspicion of late-onset sepsis. Results The study comprised 199 preterm infants with a mean {GA} of 29.1 ± ۱٫۴ weeks and a mean birth weight of 1173 ± ۲۱۰ g, who received a placebo (group C, n = ۵۲) or probiotics (group P, n = ۱۴۷) from the first week of life. At the end of the supplementation period, no statistically significant differences were seen between the groups in relation to the mean body weight (group C = ۱۹۰۶ ± ۲۳ g, group P = ۱۸۷۵ ± ۱۴ g, p = ۰٫۲۵), length, or head circumference. The incidence rates of necrotizing enterocolitis and late-onset sepsis were similar in the two groups. At the corrected {GA} of 41 weeks, there were no differences between the groups with respect to anthropometric measurements or body composition analysis. Conclusions Preterm infants receiving Bifidobacterium supplements did not exhibit better postnatal growth compared with those who received placebo treatment. No adverse effects were associated with probiotic administration. Registered under ClinicalTrials.gov Identifier no. NCT01379417.

Keywords: Prematurity, Gut microflora, Safety, Sepsis, Necrotizing enterocolitis

ترجمه فارسی
این متن به صورت خودکار و توسط موتور مترجم ترجمه شده است. برای سفارش ترجمه دقیق به قسمت 'سفارش ترجمه' مراجعه کنید

عنوان: پروبیوتیک و رشد در نوزادان نارس: مطالعه کنترل شده تصادفی، {} PREMAPRO مطالعه

نویسندگان: Stephane Hays and Aurélien Jacquot and Hélène Gauthier and Christian Kempf and Anne Beissel and Odile Pidoux and Estelle Jumas-Bilak and Evelyne Decullier and Emmanuelle Lachambre and Laurence Beck and Gilles Cambonie and Guy Putet and Olivier Claris and Jean-Charles Picaud

ژورنال: Clinical Nutrition

سال: ۲۰۱۶

چکیده:
ثبت شده در ClinicalTrialsgov شناسه هیچ NCT01379417
کلمات کلیدی:   نوزاد نارس، روده فلور، ایمنی، عفونت، آنتروکولیت نکروزان

سفارش ترجمه

سفارش ترجمه

توانایی ترجمه

توانایی ترجمه

  • فیلد های زیر را به عنوان نمونه کار ترجمه کنید. دقت کنید که کیفیت ترجمه در انتخاب شما به عنوان مترجم این مقاله موثر است.


دریافت مقاله